8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Mar 16, 2026·SEC
Talphera, Inc.(TLPH)Earnings, Financials & Key Ratios
TLPH•NASDAQ
$1.02
Price updated Jul 2, 2026
AboutTalphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.Show more
- Revenue$28K
- EBITDA-$14M+5.2%
- Net Income-$14M-9.9%
- EPS (Diluted)-0.34+32.0%
- Gross Margin100%
- EBITDA Margin-51296.43%
- Operating Margin-48157.14%
- Net Margin-51035.71%
- ROE-114.16%+3.0%
TLPH Price & Volume
Talphera, Inc. (TLPH) stock price & volume — 10-year historical chart
Loading chart...
Talphera Faces Critical Liquidity and Clinical Hurdles
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding shortfall
Key Thesis Takeaways
- Talphera is currently a pre-commercial entity undergoing a high-risk strategic pivot toward the Niyad platform, characterized by a complete evaporation of revenue and persistent quarterly operating losses exceeding $3 million.
- The company's future viability is entirely contingent upon the successful execution of the NEPTUNE clinical trial, which remains threatened by a rapidly depleting cash balance of $3.8 million as of 2026Q1.
- Investors should monitor the firm's ability to secure non-dilutive funding or strategic partnerships, as the current burn rate suggests an imminent need for additional capital to sustain operations.
Verdict Logic
the company's current cash position of $3.8 million against a quarterly burn rate of roughly $3.5 million creates a severe liquidity risk that likely necessitates further dilutive financing for shareholders.
TLPH Growth Metrics
Talphera, Inc. (TLPH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-47.97%
5 Years-65.11%
3 Years-
TTM-96.3%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-22.42%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM20.41%
Return on Capital
10 Years-55.67%
5 Years-61.45%
3 Years-76.67%
Last Year-64.98%
TLPH Recent Earnings
Talphera, Inc. (TLPH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 1/12 qtrs (50%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.04+42.9%
$0.07
Rev
—
—
Q2 2026
Mar 23, 2026Metric
Actual
Est
EPS
$0.06+20.0%
$0.07
Rev
—
$580,000
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.11-46.7%
$0.07
Rev
$1,000
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.10+16.7%
$0.12
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.04vs $0.07+42.9% | — |
| Q2 2026 | Mar 23, 2026 | $0.06vs $0.07+20.0% | —vs $580,000 |
| Q4 2025 | Nov 12, 2025 | $0.11vs $0.07-46.7% | $1,000 |
| Q3 2025 | Aug 14, 2025 | $0.10vs $0.12+16.7% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Talphera, Inc. (TLPH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.02 | $43.26M | -3.00 | — | -51035.71% | -114.16% | — | |
| $10.31 | $1.43B | -1.00 | -2.75% | -43.5% | -50.65% | — | |
| $77.01 | $9.13B | 30.08 | 37.55% | 23.13% | 126.27% | — | |
| $64.39 | $1.26B | -6.62 | -43.89% | -284.18% | -87% | — | |
| $25.03 | $984.56M | 156.44 | 3.63% | 1.27% | 1.31% | — | |
| $21.90 | $1.62B | 6.64 | 18.52% | 118.91% | 47.59% | — |
Compare TLPH vs Peers
Talphera, Inc. (TLPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TLPH SEC Filings & Documents
Talphera, Inc. (TLPH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when TLPH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TLPH Frequently Asked Questions
Talphera, Inc. (TLPH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Talphera, Inc.'s revenue?
Talphera, Inc. (TLPH) reported $0.0M in revenue for fiscal year 2025.
Is TLPH profitable?
Talphera, Inc. (TLPH) reported a net loss of $14.3M for fiscal year 2025.
Dividend & Returns
What is TLPH's return on equity?
Talphera, Inc. (TLPH) has a return on equity (ROE) of -114.2%. Negative ROE indicates the company is unprofitable.
What is Talphera, Inc.'s free cash flow?
Talphera, Inc. (TLPH) had negative free cash flow of $11.3M in fiscal year 2025, likely due to heavy capital investments.